NexBio has started trials in Mexico and the US of DAS181 (Fludase) for the treatment of laboratory-confirmed influenza.

DAS181 is an investigational drug candidate that blocks the entry of the influenza virus into cells of the respiratory tract.

The trial will assess the drug’s impact on the viral load as well as its safety and tolerability.